

**CORRECTION** Open Access

# Correction: ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target

Sandra-Nadia Ngwabyt Bikeye<sup>1</sup>, Carole Colin<sup>2</sup>, Yannick Marie<sup>1</sup>, Raphaël Vampouille<sup>4</sup>, Philippe Ravassard<sup>4</sup>, Audrey Rousseau<sup>5</sup>, Blandine Boisselier<sup>1</sup>, Ahmed Idbaih<sup>1,3</sup>, Charles Félix Calvo<sup>1</sup>, Pascal Leuraud<sup>6</sup>, Myriam Lassalle<sup>6</sup>, Soufiane El Hallani<sup>1</sup>, Jean-Yves Delattre<sup>1,3</sup> and Marc Sanson<sup>1,3\*</sup>

# **Correction**

In the original article [1], the additional file two: figure S. Two (additional file 1 here) contained two identical graphs. We present here the corrected figure S2 and the corresponding legend:

# **Additional material**

**Additional file 1: Tumor spheroid characterization**. Genomic stability was examined with CGHa analysis (left = DNA profile from the initial tumor; right = DNA profile from gliomasphere at passage p28). The chromosomes are indicated on the  $\times$  axis and copy number is on y axis. Yellow indicates the normal genomic copy number, while green indicates a loss and red indicates a gain in copy number. Although some differences are observed, the comparison of both profiles shows that overall genomic profile is quite well preserved (except for an amplicon on chromosome 8 present only in the gliomasphere).

Lassalle Myriam, El Hallani Soufiane, Delattre Jean-Yves, Sanson Marc: ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. *Cancer Cell International* 2010, **10**:1.

#### doi:10.1186/1475-2867-11-10

Cite this article as: Bikeye *et al.*: Correction: ASPM-associated stem cell proliferation is involved in malignant progression of gliomas and constitutes an attractive therapeutic target. *Cancer Cell International* 2011

## Author details

<sup>1</sup>UMR975 INSERM-UPMC, GH Pitié- Salpêtrière, Paris, France. <sup>2</sup>UMR911-CRO2, Faculté de Médecine Timone, Université de la Méditerranée, Marseille, France. <sup>3</sup>Service de Neurologie Mazarin, GH Pitié- Salpêtrière, APHP, Paris, France. <sup>4</sup>Biotechnology & Biotherapy laboratory, Centre de Recherche de l'Institut du Cerveau et de la Moelle, CNRS UMR9225, INSERM UMRS 975 Université Pierre et Marie Curie, Hôpital de la Salpêtrière, Paris, France. <sup>5</sup>Service de Neuropathologie Raymond Escourolle, GH Pitié- Salpêtrière, Paris, France. <sup>6</sup>XenTech, Evry, France.

Received: 8 April 2011 Accepted: 15 April 2011 Published: 15 April 2011

## Reference

 Bikeye Ngwabyt Sandra-Nadia, Colin Carole, Marie Yannick, Vampouille Raphaël, Ravassard Philippe, Rousseau Audrey, Boisselier Blandine, Idbaih Ahmed, Calvo Félix Charles, Leuraud Pascal,

\* Correspondence: marc.sanson@psl.aphp.fr

1UMR975 INSERM-UPMC, GH Pitié- Salpétrière, Paris, France
Full list of author information is available at the end of the article

# Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit



